Highlights Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
2.73 ^USD	-6.51%		-9.60%	+103.73%

05-07	Transcript : Trevi Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
05-07	Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-20	CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2b CORAL Clinical Trial of Haduvio? for Chronic Cough in Idiopathic Pulmonary Fibrosis	12-05	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Trevi Therapeutics, Inc. Announces the Initiation of its Phase 2a RIVER Clinical Trial of Haduvio?? for Refractory Chronic Cough	11-02	CI
Trevi Therapeutics, Inc. Announces Results from Phase 2b/3 Prism Open-Label Extension Study of Haduvio in Prurigo Nodularis	13/10/23	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/08/23	CI
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/05/23	CI
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	16/03/23	AQ
Trevi Therapeutics Gets Patent Notice of Allowance for Method to Treat Chronic Cough in Idiopathic Pulmonary Fibrosis	08/03/23	MT
Trevi Therapeutics, Inc. Announces Allowance for U.S. Patent Application Covering Use of Haduvio (Nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis	08/03/23	CI
Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q3 Loss $-0.12	10/11/22	MT
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	10/11/22	AQ
Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/11/22	CI
Trevi Therapeutics Announces Positive Data from Full Set of Subjects in Phase 2 CANAL Trial of Haduvio™ in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis	19/09/22	CI
TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	11/08/22	AQ
Trevi Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	11/08/22	CI
Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q2 Loss $-0.14	11/08/22	MT
Trevi Therapeutics Inc. Reports Positive Results from the Ph2b/3 PRISM Trial of Haduvi in Treatment of Prurigo Nodularis	29/06/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Trevi Therapeutics, Inc.

Equities

TRVI

US89532M1018

Highlights

Filters